Form 8-K - Current report:
SEC Accession No. 0001213900-25-031763
Filing Date
2025-04-15
Accepted
2025-04-15 08:25:26
Documents
14
Period of Report
2025-04-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238201-8k_hoth.htm   iXBRL 8-K 25283
2 PRESS RELEASE DATED APRIL 15, 2025 ea0238201ex99-1_hoth.htm EX-99.1 18779
  Complete submission text file 0001213900-25-031763.txt   227054

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE hoth-20250409.xsd EX-101.SCH 3038
4 XBRL LABEL FILE hoth-20250409_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE hoth-20250409_pre.xml EX-101.PRE 22374
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0238201-8k_hoth_htm.xml XML 3931
Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036
Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 25837673
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)